A Randomized, Double-Blind, Placebo-Controlled Study to Determine the Effect of Suvorexant (Belsomra) on Sympathetic Neural Activity and Baroreflex Function in Patients With Chronic Insomnia
Phase of Trial: Phase IV
Latest Information Update: 12 Jun 2019
Price : $35 *
At a glance
- Drugs Suvorexant (Primary)
- Indications Insomnia
- Focus Pharmacodynamics
- 25 Apr 2019 Status changed from not yet recruiting to recruiting.
- 06 Mar 2019 Planned initiation date changed from 1 Jan 2019 to 1 Mar 2019.
- 14 Dec 2018 New trial record